ELEV (ELEV)

ELEV (ELEV) Healthcare & Pipeline Overview

Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company specializing in therapeutics for genomically defined cancer populations. Their lead asset, seribantumab, targets HER3 in advanced solid tumors with neuregulin-1 fusions. The company operates within the competitive biotechnology sector, focusing on precision oncology.

What Is the Investment Thesis for ELEV?

Elevation Oncology presents a high-risk, high-reward investment profile typical of clinical-stage biotech companies. The primary value driver is the success of the CRESTONE trial for seribantumab. Positive Phase II data could lead to significant stock appreciation, while failure would likely result in a substantial decline. The company's focus on NRG1 fusions offers a targeted approach, but the rarity of these fusions presents challenges in patient enrollment and market size. With a market cap of approximately $20 million as of June 2026, Elevation Oncology's valuation is highly sensitive to clinical trial outcomes and regulatory milestones. Upcoming data readouts from the CRESTONE trial represent key catalysts. Investors should carefully consider the clinical and regulatory risks associated with drug development before investing.

Based on FMP financials and quantitative analysis

ELEV Key Highlights

• Seribantumab is currently in Phase II CRESTONE trial for NRG1 fusion-positive advanced solid tumors.
• The company's gross margin is 36.8%.
• Elevation Oncology has a market capitalization of $21.63M.
• The company's lead program targets a specific genomic subset of cancer patients, aligning with precision medicine trends.
• Elevation Oncology's beta is 1.50, indicating higher volatility compared to the market.

Who Are ELEV's Competitors?

ELEV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ELEV's Key Strengths?

• Targeted therapy approach.
• Focus on specific genomic alterations.
• Seribantumab in Phase II clinical trials.
• Experienced management team.

What Are ELEV's Weaknesses?

• Limited financial resources.
• Reliance on a single lead program.
• High clinical trial risk.
• Small company size.

What Could Drive ELEV Stock Higher?

• Data readout from Phase II CRESTONE trial.
• Enrollment and progress in the CRESTONE trial.
• Potential for strategic partnerships or collaborations.

What Are the Key Risks for ELEV?

• Financial-distress signal — its Altman Z-Score of -4.75 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-46.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failure or negative results.
• Regulatory delays or rejection of seribantumab.
• Competition from other cancer therapies.
• Limited market size for NRG1 fusion-positive cancers.
• Dependence on a single lead program.

What Are the Growth Opportunities for ELEV?

• Expansion into Additional NRG1 Fusion-Positive Cancer Types: Elevation Oncology has the opportunity to expand the use of seribantumab beyond the initial indications targeted in the CRESTONE trial. NRG1 fusions are found in various cancer types, including lung, pancreatic, and ovarian cancers. Positive data in the CRESTONE trial could support further clinical development in these additional indications, significantly expanding the potential market for seribantumab. This expansion would require additional clinical trials and regulatory approvals, but could provide substantial long-term growth.
• Strategic Partnerships with Larger Pharmaceutical Companies: Elevation Oncology could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of seribantumab. These partnerships could provide access to additional funding, expertise, and resources, enabling the company to conduct larger clinical trials and expand its commercial reach. A successful partnership could also validate the company's technology and increase its visibility within the industry. This would likely involve licensing agreements or co-development arrangements.
• Development of Companion Diagnostics: The development of companion diagnostics to identify patients with NRG1 fusions is crucial for the success of seribantumab. Elevation Oncology could invest in the development and commercialization of companion diagnostics to ensure that patients are accurately screened for NRG1 fusions. This would improve patient selection for clinical trials and, ultimately, for commercial use. Companion diagnostics would also help to streamline the identification of eligible patients, improving the efficiency of the treatment process.
• Exploration of HER3-Targeting Therapies Beyond NRG1 Fusions: While Elevation Oncology's primary focus is on NRG1 fusions, the company could explore the potential of HER3-targeting therapies in other cancer types. HER3 is overexpressed in various cancers, and targeting HER3 may have therapeutic benefit even in the absence of NRG1 fusions. This would require additional research and development, but could significantly expand the company's pipeline and market potential. This strategy would involve exploring different mechanisms of action and patient populations.
• Geographic Expansion into International Markets: Elevation Oncology could expand its operations into international markets, such as Europe and Asia, to reach a larger patient population. This would require establishing clinical trial sites in these regions and obtaining regulatory approvals from international authorities. Geographic expansion could significantly increase the commercial potential of seribantumab. This expansion would involve navigating different regulatory landscapes and healthcare systems.

What Opportunities Does ELEV Have?

• Expansion into additional cancer types.
• Strategic partnerships with larger companies.
• Development of companion diagnostics.
• Positive clinical trial results.

What Threats Does ELEV Face?

• Clinical trial failure.
• Regulatory hurdles.
• Competition from other therapies.
• Limited market size for NRG1 fusions.

What Are ELEV's Competitive Advantages?

• Proprietary anti-HER3 monoclonal antibody (seribantumab).
• Focus on a specific genomic subset of cancer patients (NRG1 fusions).
• Clinical-stage development with potential for market exclusivity.

What Does ELEV Do?

Elevation Oncology, Inc., founded in 2019 and based in New York before relocating to Boston, is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies. The company focuses on treating cancer in genomically defined patient populations. Their primary focus is seribantumab, a human anti-HER3 monoclonal antibody. Seribantumab is currently undergoing a Phase II CRESTONE trial, evaluating its efficacy in treating advanced solid tumors that harbor neuregulin-1 (NRG1) fusions. These fusions are rare genomic alterations that drive tumor growth and are found in various cancer types. Elevation Oncology's strategy revolves around identifying and developing therapies for specific genomic subsets of cancer patients, aligning with the growing trend of precision medicine in oncology. The company aims to improve outcomes for patients with limited treatment options by targeting the underlying genetic drivers of their disease. Elevation Oncology operates primarily in the United States, conducting clinical trials and seeking regulatory approval for its therapies.

What Products and Services Does ELEV Offer?

• Develop therapeutics for cancer treatment.
• Focus on genomically defined patient populations.
• Lead program: seribantumab, an anti-HER3 monoclonal antibody.
• Conduct Phase II CRESTONE trial for advanced solid tumors.
• Target neuregulin-1 (NRG1) fusions in tumors.
• Engage in clinical-stage biopharmaceutical research.

How Does ELEV Make Money?

• Develop and commercialize targeted cancer therapies.
• Focus on licensing or partnering for commercialization.
• Generate revenue through future drug sales, licensing, or acquisition.

What Industry Does ELEV Operate In?

Elevation Oncology operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. Precision oncology, the focus of Elevation Oncology, is a growing trend, with increasing emphasis on targeting specific genomic alterations in cancer. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms developing targeted therapies. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies. The biotechnology sector is experiencing growth, fueled by advancements in genomics and personalized medicine.

Who Are ELEV's Key Customers?

• Cancer patients with NRG1 fusions.
• Oncologists and medical professionals.
• Hospitals and cancer treatment centers.

How ELEV Is Valued

ELEV carries a market capitalization of $21.63M, placing it in the micro-cap category. Relative to its peer group, ELEV's quantitative score of 47/100 is below the peer average of 76/100.

ROE -46%Key Financial Metrics

Return on equity for ELEV stands at -46.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.0%, showing how much profit it generates from its asset base. A current ratio of 19.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -114.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

ELEV's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.75 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project ELEV revenue of about $0 for fiscal 2026, with EPS near $-0.51.

ELEV Financials

ELEV Latest News

No recent news available for ELEV.

ELEV Analyst Consensus

ELEV MoonshotScore

Common Questions About ELEV (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources